Skip to main content
B

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 Shenzhen Stock Exchange Manufacturing
Filings indexed 1,650 across all filing types
Latest filing 2026-01-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于BPI-572270胶囊获得临床试验批准通知书的公告
Regulatory Filings
2026-01-27 Chinese
关于投资杭州知兴制药有限公司的公告
Regulatory Filings
2026-01-09 Chinese
关于选举第五届董事会职工代表董事的公告
Regulatory Filings
2025-12-31 Chinese
关于投资杭州贝橙创业投资合伙企业(有限合伙)的进展公告
Regulatory Filings
2025-12-31 Chinese
2025年第二次临时股东大会决议公告
Regulatory Filings
2025-12-31 Chinese
国浩律师(杭州)事务所关于贝达药业股份有限公司2025年第二次临时股东大会的法律意见书
Regulatory Filings
2025-12-31 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.